A detailed history of Allworth Financial LP transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 6 shares of KRYS stock, worth $929. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6
Previous 7 14.29%
Holding current value
$929
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 30, 2025

SELL
$156.64 - $199.61 $156 - $199
-1 Reduced 14.29%
6 $0
Q3 2024

Oct 23, 2024

SELL
$174.7 - $213.66 $349 - $427
-2 Reduced 22.22%
7 $1,000
Q2 2024

Jul 23, 2024

BUY
$153.12 - $183.64 $459 - $550
3 Added 50.0%
9 $1,000
Q1 2024

Apr 25, 2024

BUY
$108.01 - $179.35 $432 - $717
4 Added 200.0%
6 $1,000
Q2 2022

Jul 13, 2022

BUY
$48.93 - $73.47 $97 - $146
2 New
2 $0

Others Institutions Holding KRYS

About Krystal Biotech, Inc.


  • Ticker KRYS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,664,300
  • Market Cap $3.97B
  • Description
  • Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...
More about KRYS
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.